XML 21 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 17, 2025
Jun. 30, 2024
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Registrant Name ProKidney Corp.    
Entity Central Index Key 0001850270    
Entity File Number 001-40560    
Entity Tax Identification Number 98-1586514    
Entity Incorporation, State or Country Code E9    
Entity Address, Address Line One 2000 Frontis Plaza Blvd    
Entity Address, Address Line Two Suite 250    
Entity Address, City or Town Winston-Salem    
Entity Address, State or Province NC    
Entity Address, Postal Zip Code 27103    
City Area Code 336    
Local Phone Number 999-7028    
Document Transition Report false    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Small Business true    
Entity Public Float     $ 232,629,556
Entity Emerging Growth Company true    
ICFR Auditor Attestation Flag false    
Entity Ex Transition Period false    
Title of 12(b) Security Class A ordinary shares, $0.0001 par value per share    
Trading Symbol PROK    
Security Exchange Name NASDAQ    
Auditor Name Ernst & Young LLP    
Auditor Firm ID 42    
Auditor Location Raleigh, North Carolina, United States    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of ProKidney Corp. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, changes in redeemable noncontrolling interest and shareholders’ deficit / members’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

    
Common Class A [Member]      
Document Information [Line Items]      
Entity Common Stock, Shares Outstanding   129,536,121  
Common Class B [Member]      
Document Information [Line Items]      
Entity Common Stock, Shares Outstanding   163,161,528